Below, we describe LGMD subtypes due to mutations in sarcoglycans, dystroglycan, and dysferlin and the current status of anti-inflammatory/anti-fibrotic strategies for these LGMD subtypes (summarized in Table 3). The gene discussed is DAG1; the disease is limb-girdle muscular dystrophy.